KRAS and neoplasm: In tumor cells, Nrf2 is usually activated by ROS-induced oncogenes, such as KRAS and c-MYC (DeNicola, 2011), and inhibition of its activity may contribute to the apoptosis of tumor cells and abrogated tumor growth (Ryoo et al., 2016).